As global health threats continue to evolve rapidly, pharmaceutical leaders face mounting pressure to design development programs that can withstand volatility. From pandemics to geopolitical unrest ...
Approximately 70 million people that live, work or vacation in areas of the U.S. in which Lyme disease is endemic could potentially benefit from pre-exposure prophylaxis TNX-4800 was studied in a ...
Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and ...
In February 2025, the Office of Inspector General (OIG) for the US Department of Health and Human Services issued favorable advisory opinions Advisory Opinion 24-10 and Advisory Opinion 24-12, ...
The Department of Health and Human Services, Office of Inspector General (“OIG”) recently released a favorable advisory opinion, OIG Advisory Opinion No. 24-11 (the “Opinion”), to a pharmaceutical ...
The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological ...
Pharmaceutical companies are divided over the Trump administration's faster review process for critical drugs, with concerns over potential legal risks and the future credibility of FDA decisions. The ...
SPOKANE, Wash. -- A new partnership is emerging with the goal of fast-tracking pharmaceutical manufacturing training in Spokane. Spokane Community College is teaming up with Jubilant HollisterStier ...
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist, on Tuesday. The U.S. Food and Drug Administration (FDA) ...
The latest update is out from Daito Pharmaceutical Co., Ltd. ( ($JP:4577) ). Daito Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company ...
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results